Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vegenics, a subsidary of Circadian Technologies, has secured FDA approval for its Investigational New Drug (IND) application to commence clinical trials with VGX-100 drug, used to treat cancer patients with solid tumors.
Subscribe to our email newsletter
VGX-100 is a human antibody that acts against the human VEGF-C protein.
VGX-100 when combined with Avastin and chemotherapy, demonstrated reduced tumour growth and tumour spread, and improved tumour inhibition, in animal models.
The Phase I study will evaluate VGX-100 in patients with a variety of late stage cancers.
Circadian Technologies CEO Robert Klupacs said the company expects to start clinical trials before the end of 2011, with results to be available in the second half of 2012.